EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain

Eitan Kerem iD, Annalisa Orenti iD, Arianna Adamoli, Elpis Hatziagorou iD, Lutz Naehrlich, Isabelle Sermet-Gaudelus iD, and the ECFS Patient Registry Steering Group

European Respiratory Journal · 2024-03 · 63 (3) · 2301241

DOI: 10.1183/13993003.01241-2023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 01.02.2024. Verfasst von Eitan Kerem und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and CF Centre, Hebrew University Medical School, Hadassah Medical Center, Jerusalem, Israel kerem@hadassah.org.il. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prognosis and disease severity in cystic fibrosis (CF) are linked to declining lung function. To characterise lung function by the number of adults in countries with different levels of Gross National Income (GNI), data from the European Cystic Fibrosis Society Patient Registry were utilised.

Methods

Annual data including age, forced expiratory volume in 1 s (FEV 1 ), anthropometry, genotype, respiratory cultures and CF-related diabetes (CFRD) were retrieved between 2011 and 2021. All countries were stratified into GNI per capita to reflect differences within Europe.

Results

A consistent improvement in FEV 1 % pred and survival was observed among the 47 621 people with CF (pwCF), including subjects with chronic Pseudomonas aeruginosa infection, CFRD and/or undernutrition. Mean values of FEV 1 % pred changed from 85% to 94.2% for children and from 63.6% to 74.7% for adults. FEV 1 % pred further increased among those carrying the F508del mutation in 2021, when elexacaftor/tezacaftor/ivacaftor was available. The number of adult pwCF increased from 13 312 in 2011 to 21 168 in 2021, showing a 60% increase. PwCF living in European lower income countries did not demonstrate a significant annual increase in FEV 1 % pred or in the number of adults.

Conclusion

This pan-European analysis demonstrates a consistent improvement in FEV 1 % pred, number of adult pwCF and survival over the last decade only in European higher and middle income countries. Urgent action is needed in the lower income countries where such improvement was not observed. The notable improvement observed in pwCF carrying the F508del mutation emphasises the need to develop treatments for all CF mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisChildAdultHumansCystic Fibrosis Transmembrane Conductance RegulatorLongevityEuropeMutationLung

Substanzen

Cystic Fibrosis Transmembrane Conductance Regulator

Autor:innen und Institutionen

  • Department of Paediatrics and CF Centre, Hebrew University Medical School, Hadassah Medical Center, Jerusalem, Israel kerem@hadassah.org.il.
  • Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Biometry and Epidemiology "G.A. Maccaccaro", University of Milan, Milan, Italy.
  • Paediatric Pulmonology and Cystic Fibrosis Unit, 3rd Paediatric Department, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • These authors contributed equally to the manuscript.
  • Department of Pediatrics, Justus Liebig University Giessen, Giessen, Germany.
  • Cystic Fibrosis National Pediatric Reference Center, Pneumo-Allergologie Pédiatrique, Hôpital Necker Enfants Malades, AP-HP, Paris, France.

ORCID-Profile: Eitan Kerem, Annalisa Orenti, Elpis Hatziagorou, Isabelle Sermet-Gaudelus

Zitieren

APA

Kerem, E., Orenti, A., Adamoli, A., Hatziagorou, E., Naehrlich, L., Sermet-Gaudelus, I., & and the ECFS Patient Registry Steering Group (2024). Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain. European Respiratory Journal, 63(3), 2301241. https://doi.org/10.1183/13993003.01241-2023

Vancouver

Kerem E, Orenti A, Adamoli A, Hatziagorou E, Naehrlich L, Sermet-Gaudelus I, et al. Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain. European Respiratory Journal. 2024;63(3):2301241. doi:10.1183/13993003.01241-2023

BibTeX
@article{Kerem2024,
  author = {Kerem, Eitan and Orenti, Annalisa and Adamoli, Arianna and Hatziagorou, Elpis and Naehrlich, Lutz and Sermet-Gaudelus, Isabelle and and the ECFS Patient Registry Steering Group, and the ECFS Patient Registry Steering Group},
  title = {Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain},
  journal = {European Respiratory Journal},
  year = {2024},
  volume = {63},
  number = {3},
  pages = {2301241},
  doi = {10.1183/13993003.01241-2023}
}
Kostenlos starten →